[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603572":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":20,"locations":32,"responsibleParty":126,"collaborators":10,"id":128,"slug":129,"hasResults":130,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":130,"sex":135,"minAge":136,"maxAge":10,"enrollmentInfo":137,"targetDuration":10,"studyType":140,"phases":10,"briefSummary":141,"conditions":142,"keywords":144,"overallStatus":148,"whyStopped":10,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":158},{"fullName":5,"class":6},"National Health Research Institutes, Taiwan","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"anaplastic thyroid cancer (ATC)",null,"Pathologically or cytologically confirmed ATC and diagnosed after 2015.",[13,17],{"name":14,"affiliation":15,"role":16},"Tsang-Wu Liu Taiwan Cooperative Oncology Group,NHRI,Taipei, Taiwan, M.D. PhD","Taiwan Cooperative Oncology Group,NHRI,Taipei, Taiwan","STUDY_CHAIR",{"name":18,"affiliation":15,"role":19},"Hui-Jen Tsai Taiwan Cooperative Oncology Group,NHRI,Taipei, Taiwan, M.D. PhD","PRINCIPAL_INVESTIGATOR",[21,27],{"name":22,"role":23,"phone":24,"phoneExt":25,"email":26},"Wei-Lien Feng Taiwan Cooperative Oncology Group,NHRI,Taipei, Taiwan, M.S.N.","CONTACT","+886-02-26534401","21012","winnif@nhri.edu.tw",{"name":28,"role":23,"phone":29,"phoneExt":30,"email":31},"Chien-Ya Hung Taiwan Cooperative Oncology Group,NHRI,Taipei, Taiwan, B.S.N.","+886-3-7206166","65112","951106@nhri.edu.tw",[33,48,59,70,81,92,100,107,115],{"facility":34,"status":10,"city":35,"state":36,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Taipei Veterans General Hospital","Taipei","Taiwan\u002FTaipei","Taiwan","TW",{"type":40,"coordinates":41},"Point",[42,43],121.52639,25.05306,{"lat":43,"lon":42},[46],{"name":47,"role":23,"phone":10,"phoneExt":10,"email":10},"Chun-Yu Liu",{"facility":49,"status":10,"city":50,"state":10,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"Kaohsiung Medical University","Kaohsiung City",{"type":40,"coordinates":52},[53,54],120.31333,22.61626,{"lat":54,"lon":53},[57],{"name":58,"role":23,"phone":10,"phoneExt":10,"email":10},"Jeng-Shiun Du",{"facility":60,"status":10,"city":61,"state":10,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"National Taiwan University Hospital ,NTUH Hsin-Chu Branch","Sindian City",{"type":40,"coordinates":63},[64,65],121.53111,24.94062,{"lat":65,"lon":64},[68],{"name":69,"role":23,"phone":10,"phoneExt":10,"email":10},"Jih-Hsiang Lee",{"facility":71,"status":10,"city":72,"state":10,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"China Medical University Hospital","Taichung",{"type":40,"coordinates":74},[75,76],120.6839,24.1469,{"lat":76,"lon":75},[79],{"name":80,"role":23,"phone":10,"phoneExt":10,"email":10},"Chen-Yuan Lin",{"facility":82,"status":10,"city":83,"state":10,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"National Cheng Kung University Hospital","Tainan",{"type":40,"coordinates":85},[86,87],120.21333,22.99083,{"lat":87,"lon":86},[90],{"name":91,"role":23,"phone":10,"phoneExt":10,"email":10},"Hui-Jen Tsai, MD, PhD",{"facility":93,"status":10,"city":35,"state":10,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":94,"geoPoint":96,"contacts":97},"Koo Foundation Sun Yat-Sen Cancer Center",{"type":40,"coordinates":95},[42,43],{"lat":43,"lon":42},[98],{"name":99,"role":23,"phone":10,"phoneExt":10,"email":10},"Kuo-Chen Huang",{"facility":101,"status":10,"city":35,"state":10,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":102,"geoPoint":104,"contacts":105},"National Taiwan University Hospital",{"type":40,"coordinates":103},[42,43],{"lat":43,"lon":42},[106],{"name":69,"role":23,"phone":10,"phoneExt":10,"email":10},{"facility":108,"status":10,"city":35,"state":10,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":109,"geoPoint":111,"contacts":112},"Tri-Service General Hospital",{"type":40,"coordinates":110},[42,43],{"lat":43,"lon":42},[113],{"name":114,"role":23,"phone":10,"phoneExt":10,"email":10},"Jen-Hua Yeh",{"facility":116,"status":10,"city":117,"state":10,"zip":10,"country":37,"countryCode":38,"cosmosGeoPoint":118,"geoPoint":122,"contacts":123},"CHANG GUNG MEMORIAL HOSPITAL, Linkou","Taoyuan",{"type":40,"coordinates":119},[120,121],121.29696,24.99368,{"lat":121,"lon":120},[124],{"name":125,"role":23,"phone":10,"phoneExt":10,"email":10},"Chiao En Wu, MD, PhD",{"type":127,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100603572","taiwanese-anaplastic-thyroid-cancer-registry-100603572",false,"NCT07138261","Taiwanese Anaplastic Thyroid Cancer Registry","TATC","Inclusion Criteria:\n\n1. Pathologically or cytologically confirmed ATC and diagnosed after 2015.\n2. Capable of understanding and complying with the protocol requirements and signed informed consent. The dead patient can be enrolled without signed informed consent and they were dead before 2025.6.30.\n\nExclusion Criteria:\n\n1. Inability and unwillingness to give informed consent except dead patient.\n2. Patients refuse for collection of clinical data and follow up.","ALL","18 Years",{"count":138,"type":139},100,"ESTIMATED","OBSERVATIONAL","Primary treatment strategies for ATC have included surgical resection combined with radiotherapy, chemotherapy, or concurrent chemoradiation therapy. Despite these aggressive approaches, disease recurrence or progression remains frequently observed. Recent advances in molecular diagnostics and targeted therapy development have expanded treatment options for ATC patients with actionable genetic alterations, such as BRAF mutations or NTRK fusions. Nevertheless, for patients lacking identifiable targetable mutations, therapeutic options remain limited and clinical outcomes are poor. To address this unmet clinical need, the investigators aim to analyze baseline characteristics, treatment outcomes, and biomarker profiles from a larger cohort of ATC patients, with the goal of identification of predictive biomarkers and potential therapeutic targets. Given the rarity of ATC, conducting comprehensive studies at a single institution is challenging. Therefore, the investigators propose to establish a multi-center registry to systematically collect clinical data and tumor specimens from ATC patients.",[143],"Thyroid Carcinoma, Anaplastic",[145,146,147],"Anaplastic thyroid cancer","Genetic aberrations in anaplastic thyroid cancer","Treatment for anaplastic thyroid cancer","NOT_YET_RECRUITING","2025-08-17",{"date":151,"type":152},"2025-08-22","ACTUAL",{"date":154,"type":139},"2025-09-01",{"date":156,"type":139},"2035-12-30",{"name":5,"class":6},9]